
Ostarine (Enobosarm)
Ostarine (enobosarm) is a SARM that has been in company trials since 2006 and has never been approved. Phase 2 trials found gains of about 1 to 1.5 kg of lean body mass over 3 to 4 months in healthy older adults and in people with cancer-related weight loss, and some anti-tumor activity in advanced breast cancer. Two larger phase 3 trials in people starting chemotherapy for lung cancer (POWER 1 and 2, 651 participants) posted mixed responder results on ClinicalTrials.gov: more people kept their lean mass on ostarine than on placebo, but in one trial fewer people on ostarine than on placebo improved their stair-climb power. It lowers HDL cholesterol and, in men, testosterone. Case reports describe severe liver injury in people using products sold online, and FDA warns that SARMs are linked to liver injury, heart attack and stroke risk, infertility and other harms.
Research compound: not an approved drug or dietary supplement
This compound is sold for research and is not FDA-approved for human use or as a dietary supplement. Human evidence is limited; purity and dosing of consumer products are unverified. The data below is an evidence review for education only. Talk to a clinician before considering it.
Quick decision guide
May help most
No approved or proven use; research participants in registered clinical trials only
Common dosing range
No approved or established dose. Company trials gave 0.1 to 3 mg by mouth once daily for muscle loss and 9 or 18 mg daily in advanced breast cancer, under medical monitoring
When to expect effects
Lean mass changes were measured after about 12 to 16 weeks in trials
Watch out for
Not FDA-approved; FDA says SARMs cannot be legally sold as dietary supplements and that "research use only" products are unapproved drugs; FDA links SARMs to liver injury and acute liver failure, heart attack and stroke risk, infertility, testicular shrinkage and psychosis; products sold online are often mislabeled; prohibited at all times in sport (WADA 2026 list, S1.2)
What is it
Ostarine (enobosarm, also coded MK-2866 and GTx-024) is an investigational drug that is not FDA-approved for any use, and FDA says products sold as SARMs cannot be legally marketed in the US as a dietary supplement or a drug. It is a nonsteroidal selective androgen receptor modulator (SARM): a lab-made compound that acts on the same receptor as testosterone. It was developed by the drug company GTx, Inc., which tested it from 2006 in trials for muscle loss in older adults and in people with cancer, for advanced breast cancer and for stress urinary incontinence in women; later trials are sponsored by Veru Inc. On ClinicalTrials.gov today, a phase 2 trial of enobosarm in people taking semaglutide for weight loss (NCT06282458, 168 participants) is listed as completed with no results posted, and a phase 2b trial (PLATEAU, NCT07446998) is active and not recruiting, with its primary completion estimated for October 2027. Products sold online as "Ostarine" or "MK-2866", including those labeled "research use only" or "not for human consumption", are not the trial drug: FDA calls them unapproved new drugs, and an independent lab analysis found many were mislabeled.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
lean body mass and stair climbing in healthy older adults Limited Evidence | About 1.3 kg more lean mass than placebo at 3 mg daily over 12 weeks | Research participants in controlled trials only | 12 weeks |
muscle loss in people with cancer (cancer cachexia) Limited Evidence | Median lean mass gain of 1.0 to 1.5 kg from baseline over about 16 weeks, against no change on placebo | People with cancer-related weight loss taking part in controlled trials | About 16 weeks (day 113) |
advanced breast cancer that is androgen receptor positive Limited Evidence | Clinical benefit at 24 weeks in about 3 in 10 women, with no comparison group | Women with advanced androgen receptor-positive breast cancer enrolled in oncology trials | Assessed at 16 to 24 weeks |
lean body mass and stair climbing in healthy older adults
- Effect
- About 1.3 kg more lean mass than placebo at 3 mg daily over 12 weeks
- Best fit
- Research participants in controlled trials only
- Time
- 12 weeks
muscle loss in people with cancer (cancer cachexia)
- Effect
- Median lean mass gain of 1.0 to 1.5 kg from baseline over about 16 weeks, against no change on placebo
- Best fit
- People with cancer-related weight loss taking part in controlled trials
- Time
- About 16 weeks (day 113)
advanced breast cancer that is androgen receptor positive
- Effect
- Clinical benefit at 24 weeks in about 3 in 10 women, with no comparison group
- Best fit
- Women with advanced androgen receptor-positive breast cancer enrolled in oncology trials
- Time
- Assessed at 16 to 24 weeks
Evidence for 3 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
lean body mass and stair climbing in healthy older adults
Biomarker supportIn a 12-week phase 2 trial run by the developer GTx, 120 healthy men over 60 and postmenopausal women were randomly assigned to placebo or ostarine 0.1, 0.3, 1 or 3 mg daily. At 3 mg, lean body mass measured by DXA rose by an average of 1.3 kg more than placebo (P < 0.001); the 1 mg dose gave 0.7 kg more than placebo, which was not statistically significant (P = 0.055). Fat mass fell by about 0.6 kg relative to placebo at 3 mg, and body weight did not change. Stair-climb power improved at 3 mg (P = 0.013 vs placebo). The same trial found a dose-dependent drop in HDL cholesterol (17% at 1 mg and 27% at 3 mg) and, in men, lower total testosterone and SHBG. The trial was small, short and company-run; it did not measure falls, fractures, disability or long-term safety.
Bottom line: One small company trial showed a modest gain in lean mass, with a drop in HDL cholesterol; it was never approved for this use.
muscle loss in people with cancer (cancer cachexia)
Biomarker supportIn a phase 2 trial funded by GTx, 159 men over 45 and postmenopausal women with cancer and at least 2% weight loss in the previous 6 months received ostarine 1 mg, 3 mg or placebo daily for up to 113 days. In the 100 people with usable scans, median lean body mass rose 1.5 kg on 1 mg and 1.0 kg on 3 mg and did not change on placebo (0.02 kg). Stair-climb power also rose in both ostarine groups. These gains were compared with each group's own starting point, not tested against placebo. Serious adverse events, most often cancer progression, were similar across groups and none were judged related to the drug; 3 people on 3 mg had temporary rises in the liver enzyme ALT to 2 to 3 times normal. The company then ran two phase 3 trials of 3 mg daily for 147 days in people starting chemotherapy for non-small-cell lung cancer (POWER 1 and 2), with stair-climb power and lean body mass as co-primary endpoints analyzed as responder rates. Ostarine has not been approved for cancer-related muscle loss.
Bottom line: A phase 2 trial showed lean mass gains in people with cancer; larger phase 3 trials followed and the drug was not approved.
advanced breast cancer that is androgen receptor positive
Disease adjunctIn an open-label phase 2 trial funded by GTx at 35 centers in 9 countries, 136 postmenopausal women with previously treated ER-positive, HER2-negative advanced breast cancer were randomly assigned to ostarine 9 mg or 18 mg daily, with no placebo group. Among the 102 with confirmed androgen receptor-positive tumors, 32% (9 mg) and 29% (18 mg) had clinical benefit at 24 weeks. Serious (grade 3 or 4) drug-related side effects occurred in 8% (9 mg) and 16% (18 mg), most often raised liver enzymes (4% and 3%), high blood calcium (3% and 3%) and fatigue. In a separate small phase 2 trial in 16 evaluable patients with androgen receptor-positive metastatic triple-negative breast cancer, ostarine 18 mg daily plus pembrolizumab gave a clinical benefit rate of 25% at 16 weeks; that trial stopped early because the drug supply was withdrawn. Neither trial compared ostarine with standard treatment, and neither measured survival against a control group.
Bottom line: Uncontrolled trials showed some anti-tumor activity in advanced breast cancer; no approval followed.
How it works
How to take it
What to track
Bottom line: No dose is approved or established, and the products sold online were never tested in trials.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Severe liver injury. Case reports describe liver injury, mostly cholestatic and often with jaundice, in people who used products sold as ostarine (enobosarm): a man in his early 40s with jaundice after about 2 months of use, whose liver tests improved gradually over several months; a 31-year-old man with itching and dark urine (hepatocellular injury, without jaundice) about 3 weeks after starting a muscle-building product containing enobosarm, who improved after stopping; a 24-year-old man whose bilirubin exceeded 30 mg/dL and who needed albumin dialysis (MARS), with bilirubin back to normal about 6 months after he started the product; two young men who had used ligandrol and/or ostarine for a few weeks followed by other "post-cycle" substances, who recovered after 3 months; and a 66-year-old man who used ostarine with other unapproved products bought online. In most reports the product was not analyzed, so other ingredients cannot be ruled out. FDA lists liver injury and acute liver failure among the serious problems linked to SARMs.
Heart attack and stroke risk, and lower HDL cholesterol. In a 2017 warning letter to a company selling ostarine and LGD-4033, FDA states that SARMs have the potential to increase the risk of heart attack and stroke, and that their long-term safety, including effects on blood lipids, remains unclear. In the 12-week trial in older adults, HDL cholesterol fell by 17% at 1 mg and 27% at 3 mg daily.
Hormone and fertility effects. In men in the 12-week trial, total testosterone fell (by about 7 nmol/L at 3 mg) along with SHBG. FDA lists infertility, testicular shrinkage, sexual dysfunction and pregnancy miscarriage among the problems that studies and reports associate with SARMs.
Psychiatric and sleep effects. FDA lists psychosis or hallucinations and sleep disturbances among serious or life-threatening problems associated with SARMs, and says it continues to receive adverse event reports, with the real number likely higher because of underreporting.
Mislabeled and unapproved products. In a 2016 analysis of 44 products sold online as SARMs, only 23 (52%) contained a SARM (ostarine, LGD-4033 or andarine), 17 (39%) contained another unapproved drug, 11 (25%) contained substances not on the label, 4 (9%) contained no active compound, and the amount matched the label in only 18 (41%). In December 2025, FDA issued a warning letter to a seller of "MK-2866" (ostarine) labeled "RESEARCH USE ONLY" and "not for human consumption", stating that the products are unapproved new drugs intended for human use.
Who should avoid it
- Anyone outside a supervised clinical trial: FDA says SARMs are not approved, have not been reviewed for safety or efficacy, and that consumers should be advised against using them
- Teenagers and young adults, the group FDA says social media sellers and influencers target
- People with liver disease or a history of jaundice: liver injury is the most often reported serious harm with SARMs
- People with heart disease, risk factors for heart attack or stroke, or low HDL cholesterol
- Athletes tested under anti-doping rules: SARMs have been prohibited at all times since 2008, and the 2026 WADA Prohibited List names enobosarm (ostarine) under S1.2, other anabolic agents
Pregnancy & breastfeeding
There are no human data on ostarine in pregnancy or breastfeeding; the trials in women enrolled only postmenopausal women. FDA lists infertility and pregnancy miscarriage among the problems linked to SARMs. Avoid use if you are pregnant, breastfeeding or trying to conceive, and talk to your doctor.
Interactions
In company-run phase 1 drug interaction studies, rifampin lowered ostarine levels in the blood (peak level down 23%, total exposure down 43%). The study authors judged the overall risk of clinically relevant drug interactions to be low. This was tested only with the pharmaceutical product.
In company-run phase 1 drug interaction studies, probenecid raised blood levels of ostarine (total exposure up 50%) and of its main breakdown product (up 112%). The study authors judged the overall risk of clinically relevant drug interactions to be low. This was tested only with the pharmaceutical product.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is ostarine FDA-approved?⌄
No. Ostarine (enobosarm) is not approved for any use. It remains an investigational drug: on ClinicalTrials.gov, a phase 2 trial in people taking semaglutide for weight loss is listed as completed with no results posted, and a phase 2b trial sponsored by Veru Inc. is active and not recruiting. FDA states that SARMs are not FDA approved.
Is it legal to buy ostarine as a supplement or a research chemical?⌄
FDA says SARMs cannot be legally marketed in the US as a dietary supplement or a drug at this time, and that products marketed as supplements or "sold for research use only" are considered unapproved drugs. FDA has sent warning letters to sellers of ostarine since at least 2017, including in December 2025, and says it has also pursued criminal actions against distributors.
What did the ostarine trials actually show?⌄
Company-run phase 2 trials found modest gains in lean body mass: about 1.3 kg more than placebo over 12 weeks at 3 mg daily in healthy older adults, and a median 1.0 to 1.5 kg over about 16 weeks in people with cancer-related weight loss. Two phase 3 trials in 651 people starting chemotherapy for lung cancer (POWER 1 and 2) posted results on ClinicalTrials.gov, not in a full published paper that we could find: lean mass was maintained in 41.9% on ostarine vs 30.4% on placebo in one trial and 46.5% vs 37.9% in the other, but stair-climb power improved by at least 10% in 29.4% vs 24.2% in one and in 19.5% vs 24.8% (fewer on ostarine) in the other. A phase 2 trial in 491 women with stress urinary incontinence posted similar responder numbers for ostarine and placebo (94 and 96 of 163 vs 87 of 165). No published trial has tested whether it improves strength or sports performance in young, healthy people.
Can ostarine damage the liver?⌄
Case reports describe serious liver injury with jaundice in people who used products sold as ostarine, including one young man who needed albumin dialysis and took about 6 months to recover. In company trials, raised liver enzymes were also seen, for example in 5 of 24 people on 3 mg daily in the 12-week trial in older adults. FDA lists liver injury and acute liver failure among the harms linked to SARMs. Anyone with yellow skin or eyes, dark urine or severe itching should get prompt medical care.
Is ostarine banned in sport?⌄
Yes. The 2026 WADA Prohibited List names enobosarm (ostarine) as a SARM under S1.2, other anabolic agents, which are prohibited at all times, in and out of competition. Athletes should check the current list with their anti-doping organization.
Can I take ostarine with my supplements or medicines?⌄
The only published interaction studies we found were company-run phase 1 studies of the pharmaceutical product: rifampin lowered ostarine levels by 43% and probenecid raised them by 50%, while itraconazole had no effect and ostarine did not change levels of celecoxib or rosuvastatin. No studies have tested it with supplements, and products sold online may contain other drugs. Ask a doctor or pharmacist to review your full list, and tell them if you have used ostarine.
References by claim
lean body mass and stair climbing in healthy older adults
Dalton et al., 2011 · PMC (2011) link
muscle loss in people with cancer (cancer cachexia)
advanced breast cancer that is androgen receptor positive
Safety
Bedi et al., 2021 · PMC (2021) link
Weinblatt et al., 2022 · PMC (2022) link
Mertens et al., 2024 · PubMed (2024) link
Koller et al., 2021 · PMC (2021) link
Cuba et al., 2026 · PubMed (2026) link
Adolf et al., 2026 · PubMed (2026) link
FDA Consumer Update: FDA Warns of Use of Selective Androgen Receptor Modulators (SARMs) Among Teens, Young Adults · FDA link
FDA warning letter to Panther Sports Nutrition (October 23, 2017): products labeled to contain ostarine and LGD-4033 · FDA link
Van Wagoner et al., 2017 · PMC (2017) link
Vignali et al., 2023 · PMC (2023) link
WADA Prohibited List (current list, S1.2 Other anabolic agents: SARMs, e.g. enobosarm (ostarine), LGD-4033 (ligandrol)) · World Anti-Doping Agency link
Interaction: Rifampin
Coss et al., 2016 · PubMed (2016) link
Track Ostarine (Enobosarm) with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This compound is not approved by the FDA for human use and is not a dietary supplement. This page is an educational review of available research (much of it preclinical or early-stage), not a recommendation to use it. Consumer product quality is unregulated. Consult a qualified clinician.
